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	 Metformin	 hydrochloride	 was	 quantified	 in human	 plasma	 by	 Ultra	 Performance	 Liquid
Chromatography	with	Tandem	Mass	spectrometric	determination	(UPLC‐MS/MS).	The	mobile
phase	used	was	(Water	+	0.1%	Formic	acid)	and	(Acetonitrile	+	0.1%	Formic	acid)	in	the	ratio
of	80:20	(v:v).	An	Acquity	UPLC	HSS	T3	1.8	um	2.1×50	mm	column	was	used.	The	detection
was	 performed	 on	 a	 mass	 spectrometer	 (ESI+)	 using	 chlorpheniramine	 as	 an	 internal
standard.	 The	 method	 was	 fully	 validated	 and	 it	 was	 applied	 to	 bioequivalence	 study	 of
metformin	hydrochloride	in	two	brands	of	the	drug	with	relative	bioequivalence	of	94.7%.	
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1.	Introduction	
	
Metformin	hydrochloride	 is	N,N‐dimethyldiguanide	hydro	
chloride	 (Figure	 1).	 It	 is	 an	 inexpensive	 biguanide	 oral	 anti	
hyperglycemic	agent	 [1],	 it	 exerts	 its	glucose‐lowering	effects	
primarily	through	increased	hepatic	insulin	sensitivity	and	the	
resultant	 suppression	 of	 hepatic	 glucose	 output.	 Metformin	
hydrochloride	may	 also	modestly	 enhance	 glucose	 uptake	 in	
peripheral	 tissues	 and	 increase	 glucose	 metabolism	 in	 the	
splanchnic	 bed	 [2].	 It	 is	 also	 used	 for	 diabetes	 prevention,	
particularly	 in	 overweight	 obese	 people	 and	 those	 with	
unimpaired	renal	function	[3].		
	
	
	
Figure	1.	Structure	of	metformin	hydrochloride	 (a)	 and	chlorpheniramine	
(b).	
Our	 goal	 is	 to	 develop	 and	 validate	 a	 fast	 bio	 analytical	
method	 for	 the	 analysis	 of	 metformin	 hydrochloride	 to	
support	 bioequivalence	 studies.	 Direct	 injection	 of	 the	
extracted	 samples	 is	 preferred.	 Analysis	 of	 metformin	
hydrochloride	 is	 a	 challenge	 owing	 to	 its	 high	 polarity	 and	
small	 molecular	 size,	 which	 lead	 to	 poor	 retention	 of	
metformin	 hydrochloride	 on	 reversed‐phase	 liquid	
chromatographic	 columns.	 There	 have	 been	 some	 published	
applications,	which	used	reversed‐phase	columns	such	as	C18	
and	 C8.	 Highly	 aqueous	 mobile	 phases	 were	 used	 for	 the	
analyte	retention.	High	organic	extracts	are	not	conducible	for	
direct	 injection	 onto	 reversed	 phase	 columns	 with	 highly	
aqueous	 mobile	 phases,	 which	 may	 lead	 to	 poor	
chromatograms	 with	 peak	 broadening	 and	 distortion	 [4‐6].	
Therefore,	many	 of	 these	 applications	 did	 not	 support	 direct	
injection	of	extracted	sample	solution	containing	high	organic	
concentration,	 thus	 requiring	 additional	 time‐consuming	
evaporation	 and	 reconstitution	 procedures	 during	 sample	
preparation.	 These	 additional	 steps	 could	 also	 lead	 to	
additional	analyte	 loss	 [7‐11].	Using	of	solid	phase	extraction	
increases	the	coast	of	the	method	to	be	applicable	for	analysis	
large	number	of	samples	 in	bioequivalence	studies	 [12].	Only	
one	 method	 was	 published	 for	 direct	 injection	 using	
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hydrophilic	 interaction	 liquid	 chromatography	 tandem	 mass	
spectrometry	 (HILIC‐MS/MS)	 [13].	 The	 present	 paper	
describes	a	fast	and	highly	sensitive	approach	that	enables	the	
determination	of	metformin	hydrochloride	at	0.20	min	with	a	
total	 analysis	 time	 of	 0.5	 min.	 Using	 Acquity	 UPLC	 HSS	 T3	
column,	 which	 is	 suitable	 for	 analysis	 of	 highly	 organic	
samples	with	direct	injection.	This	method	was	fully	validated	
and	 it	was	 applied	 to	 bioequivalence	 study	 of	 two	 brands	 of	
the	drug.		
	
2.	Experimental	
	
2.1.	Materials	
	
Metformin	hydrochloride	 and	 chlorpheniramine	 (Internal	
standard,	 IS)	 were	 purchased	 from	 Sigma	 Aldrich,	 USA,	 The	
chemical	 structures	 of	 metformin	 hydrochloride	 and	 IS	 are	
shown	in	Figure	1.	Acetonitrile	of	HPLC	grade	was	purchased	
from	 E.	 Merck,	 Darmstadt,	 Germany.	 Formic	 acid	 was	
purchased	 from	 Sigma	 Aldrich,	 USA.	 Purified	 water	 was	
processed	using	an	ELGA	Pure	Lab	Classic	water	polisher	and	
deionizing	 unit	 (Marlow,	 UK).	 Blank	 human	 plasma	 was	
purchased	 from	VACSERA,	Giza,	Egypt	 and	was	stored	 frozen	
at	‐70	°C.	All	mobile	phase	solvents	were	HPLC	grade	and	were	
filtered	 through	 0.22	μm	 filters	 (HNWP	 membrane	 filters,	
Millipore).	
	
2.2.	Instrumentations	and	chromatographic	conditions	
	
2.2.1.	Liquid	chromatography	
	
Chromatographic	 separation	 was	 performed	 on	 Waters	
UPLC	 system	 (Milford,	 Massachusetts,	 USA)	 with	 an	 auto	
sampler	and	a	column	oven	that	enabled	temperature	control	
of	the	analytical	column.	Acquity	UPLC	HSS	T3	1.8	µm	2.1×50	
mm	 column	 was	 employed	 and	 maintained	 at	 40	 °C.	 The	
mobile	 phase	 consisted	 of	 (Water	 +	 0.1%	 Formic	
acid):(Acetonitril	 +	 0.1%	 Formic	 acid)	 in	 the	 ratio	 of	 80:20	
(v:v)	 at	 an	 isocratic	 flow	 rate	 of	 0.65	mL/min.	 The	 injection	
volume	was	10	μL.	
	
2.2.2.	Mass	spectrometry	
	
Waters	 UPLC	 Xevo	 TQD	 system	 (Milford,	 Massachusetts,	
USA)	 equipped	 with	 a	 Turbo	 Ion	 spray	 interface.	 Mass	
spectrometer	 settings	 in	 positive‐ion	 mode	 (ESI+)	 with	 ion	
spray	voltage	 at	5000	V,	 temperature	at	400	 °C,	 collision	gas	
(N2)	at	15	psi,	curtain	gas	at	20	psi,	declustering	potential	(DP)	
and	collision	energy	(CE)	were	set	at	40	and	60.	Quantification	
was	performed	using	multiple	 reaction	monitoring	 (MRM)	of	
the	transitions	of	(precursor	to	product)	monitored	were	m/z	
129.93/59.99	 for	 metformin	 hydrochloride	 and	 m/z	
275.14/229.93	 for	 chlorpheniramine.	 Data	 acquisition	 and	
processing	were	performed	with	the	Analyst	software.	
	
2.3.	Calibration	standards	and	quality	control	samples	
	
Standards	and	quality	control	samples	(QCs)	of	metformin	
hydrochloride	were	 prepared	 from	 stock	 solutions	 (5	 µg/mL	
in	water).	Working	calibration	standards	at	concentrations	of	
5.00,	25.00,	50.00,	100.00,	500.00,	1000.00,	2000.00,	3000.00	
and	 4000.00	 ng/mL	 were	 prepared	 in	 blank	 plasma.	
Chlorpheniramine	was	prepared	 in	water	with	 concentration	
of	50.00	µg/mL.	Three	levels	of	QC	samples	at	10.00,	2000	and	
3000.00	ng/mL,	respectively,	were	prepared	in	plasma	for	the	
determination	of	 inter‐assay	accuracy	and	precision.	Aliquots	
of	the	standards	and	QC	samples	were	stored	frozen	at	‐70	°C.	
	
2.4.	Sample	preparation	
	
50	 µL	 of	 Chlorpheniramine	 IS	 (50	 µg/mL)	was	 added	 to	
200	 µL	 metformin	 hydrochloride	 working	 plasma	 solutions,	
Vortex	(30	s).	The	plasma	was	deprotonated	with	acetonitrile	
in	a	ratio	of	plasma:acetonitrile	(2:3,	v:v).	After	mixing	(30	s)	
and	 centrifugation	 (10	 minutes	 at	 3500	 rpm),	 10	 µL	 of	 the	
clear	 supernatant	 was	 injected	 into	 the	 liquid	 chromato‐
graphic	system	after	 filtration	 through	Whatman	Filter	paper	
No.	22.	
	
2.5.	Validation	of	UPLC/MS/MS	method	
	
The	 method	 was	 validated	 for	 accuracy,	 precision,	
sensitivity,	 recovery,	 matrix	 effect,	 specificity,	 linearity	 and	
reproducibility	 according	 to	 the	 FDA	 guidance	 for	 bio‐	
analytical	method	 validation	 [14]	 over	 a	 concentration	 range	
of	 5.00‐4000,000	 ng/mL	 using	 six	 calibration	 standards	 and	
six	 replicates	 of	 QC	 samples	 at	 each	 concentration	 level	 in	
three	 separate	 batch	 runs.	 Analyte	 stability	was	 tested	 using	
QC	 samples	 for	multiple	 freeze‐thaw	 cycles,	 on	 the	 bench	 at	
room	 temperature	 (Short‐term	 stability),	 or	 frozen	 at	 ‐70	 °C	
(Long‐term	 storage).	 Processed	 sample	 stability	 and	 stock	
solution	 stability	 were	 also	 determined.	 The	 extraction	
recovery	 of	 metformin	 hydrochloride	 was	 calculated	 by	
comparing	the	peak	areas	of	extracted	plasma	standards	with	
the	 peak	 areas	 of	metformin	 hydrochloride	 in	 the	 solvent	 at	
the	 correspond‐ding	 concentrations.	 The	 method	 specificity	
was	evaluated	by	screening	six	lots	of	blank	human	plasma.	
	
2.6.	Study	design	
	
This	was	a	randomized,	open‐label,	2	ways,	crossover	trial	
in	24	healthy	volunteers	aged	18	to	40	years,	with	body	mass	
indices	between	18	and	27	kg/m2.	Subjects	were	given	single	
oral	doses	of	 the	 following	 two	treatments	after	an	overnight	
fast:	 Mepaphage	 500	 mg	 Film	 Coated	 Tablets	 (MEPACO,	
Elsharkya,	Egypt)	and	Glucophage	500	mg	Film	Coated	Tablets	
(Merck	Sante	S.A.S.,	France)	with	250	mL	of	water.	Treatments	
were	 separated	 by	 1	 week	 washout	 periods	 between	
consecutive	doses.	Each	subject	was	randomized	to	receive	the	
two	 treatments.	 Key	 exclusion	 criteria	 included	 use	 of	
prescription	 or	 nonprescription	 drugs,	 vitamins,	 or	 dietary	
supplements	 within	 7	 days	 or	 5	 half‐lives	 (whichever	 is	
longer)	 before	 the	 first	 dose	 of	 study	medication,	 except	 for	
acetaminophen	at	doses	of	≤1	g/day;	any	clinically	significant	
disease	 or	 drug	 allergies;	 febrile	 illness	 within	 the	 5	 days	
before	 first	administration	of	 study	medication;	 sensitivity	 to	
heparin	or	heparin‐induced	thrombocytopenia;	a	positive	test	
result	for	a	drug	of	abuse;	regular	consumption	of	alcohol	and	
excessive	 tobacco	 or	 nicotine	 use	 (equivalent	 to	 5	 cigars	 per	
day).	Blood	samples	were	drawn	from	subjects	before	dosing	
and	at	0.30,	0.60,	1.00,	1.30,	1.60,	2.00,	2.50,	3.00,	3.50,	4.00,	
5.00,	6.00,	8.00,	10.00,	12.00,	24.00	and	30.00	h	post	dose	 in	
each	 treatment	 period.	 Samples	 were	 collected	 in	 6	 mL	
Vacutainer	 tubes	 (BD	 Diagnostics,	 Franklin	 Lakes,	 NJ)	 using	
heparin	as	 anticoagulant,	 then	centrifuged	at	4500	rpm	for	5	
minutes	 to	 separate	 the	 plasma.	 Plasma	 samples	 were	
transferred	 to	 two	 2	 mL	 polypropylene	 cryogenic	 tubes	
(Labeled	 retention	 sample	 and	 analyte,	 respectively)	 and	
immediately	stored	at	‐70	°C.	
	
2.7.	Statistical	analyses	
	
Non	 compartmental	 pharmacokinetic	 analysis	 was	
performed	 using	 Kinetica	 Version	 5.0	 software	 and	 the	
following	 pharmacokinetic	 parameters	 were	 calculated:	
Maximum	 plasma	 concentration	 Cmax,	 Time	 to	 reach	 Cmax	
following	 drug	 administration	 Tmax,	 AUC0‐t:	 Area	 under	 the	
plasma	 concentration‐time	 curve,	 AUC0‐inf:	 Area	 under	 the	
plasma	concentration‐time	curve	from	time	0	(administration)	
extrapolated	to	infinity,	Ke:	Terminal	elimination	rate	constant,	
t½:	Elimination	half‐life.	
	
	
	
180	 Mohammed	et	al.	/	European	Journal	of	Chemistry	6	(2)	(2015)	178‐182	
	
	
Table	1.	Accuracy	of	calibration	standards,	n	=	5.	
Statistical	parameters	 Concentration	of	metformin	hydrochloride	(ng/mL)	
5	 25	 50 100 500 1000 2000	 3000	 4000
Found	mean	plasma	conc.	 5.15	 24.8	 50.4 97.0 491.0 960.5 1910.3	 2890.6	 4078.0
SD	a	 0.10	 0.34	 0.96 1.5 2.5 11.2 14.9 23.5	 44.6
CV	b	 1.9	 1.4	 1.9 1.5 0.5 1.2 0.8 0.8	 1.1
Accuracy	percent	 102.70	 99.20 100.80 97.00 98.20 96.05 95.50	 96.35	 101.00
	a	SD,	standard	deviation.	
b	CV,	coefficient	of	variation.	
	
3.	Results	and	discussion	
	
3.1.	Chromatography	and	mass	spectrometry	
	
Metformin	 hydrochloride	 is	 a	 small	 molecule	 with	 high	
polarity.	 The	 retention	 of	 metformin	 hydrochloride	 on	
reversed‐phase	 columns	 was	 very	 poor.	 The	 use	 of	 column	
suitable	 for	 separation	 of	 high	 polar	 compounds	 as	 HSS	 T3	
permits	 the	 separation	 of	 polar	 compound	 as	 metformin	
hydrochloride.	In	order	to	minimize	the	run	time	of	the	assay,	
an	ultra‐performance	column	was	used.	The	extracted	samples	
by	 protein	 precipitation,	 which	 typically	 contain	 a	 high	
concentration	 of	 organic	 solvent	 is	 not	 compatible	 with	 the	
separation	using	reversed	column,	which	needs	high	aqueous	
mobile	 phase	 to	 be	 separated,	 while	 the	 use	 of	 ultra‐
performance	 column	 HSS	 T3	 permits	 the	 use	 of	 aqueous	
mobile	 phase	 with	 good	 separation.	 Therefore	 a	 mixture	 of	
water	with	0.1%	formic	acid:	acetonitrile	in	ratio	of	80:20	(v:v)	
was	 finally	 adopted	 as	 the	 mobile	 phase	 thus	 making	 direct	
injection	of	extracted	samples	possible.	The	total	run	time	was	
0.5	min	per	sample.	The	shortest	analysis	time	in	the	literature	
was	 2	min.	 The	 shorter	 analysis	 time	would	 better	meet	 the	
requirements	 for	 high	 sample	 throughput	 in	 bioequivalence	
study.	
The	 low	 limit	 of	 detection	 (LLOD)	 for	 metformin	
hydrochloride	 was	 5.00	 ng/mL.	 Due	 to	 the	 lower	 injection	
volume	of	10	μL,	 the	on	column	sensitivity	 in	our	study	(The	
quantity	 of	 drug	 injected	 on	 the	 column	 per	 injection)	 was	
50.00	pg	which	is	 lower	than	the	published	values.	UPLC‐MS‐
MS	 operation	 parameters	 were	 carefully	 optimized	 for	 the	
determination	 of	 metformin	 hydrochloride.	 The	 mass	
spectrometer	was	 in	positive	 ionization	modes	for	metformin	
hydrochloride.	In	the	precursor	ion	full‐scan	spectra,	the	most	
abundant	ions	were	protonated	molecules	(M+H)+	m/z	129.93,	
and	275.14	for	metformin	hydrochloride	and	I.S.,	respectively.	
The	 product	 ion	 scan	 spectra	 showed	 high	 abundance	
fragment	 ions	 at	 m/z	 59.99	 and	 229.93	 for	 metformin	
hydrochloride	 and	 I.S.,	 respectively.	 Retention	 time	 of	
metformin	 hydrochloride	 was	 0.20	 min	 and	 that	 for	
chlorpheniramine	was	0.21	min,	Figure	2.	
	
3.2.	Sample	preparation	
	
Liquid‐liquid	 extraction	 (LLE)	 and	 solid‐phase	 extraction	
(SPE)	 are	 techniques	 often	 used	 in	 the	 preparation	 of	
biological	 samples	 as	 they	 often	 improve	 the	 sensitivity	 and	
robustness	 of	 the	 assay.	 However,	 metformin	 hydrochloride	
had	a	very	high	polarity,	so	it	was	impossible	to	extract	it	from	
biological	 fluids	using	 liquid‐liquid	extraction	method.	On	the	
other	 hand,	 SPE	 would	 not	 be	 cost	 effective	 in	 a	 high	
throughput	analysis	involving	many	samples.	Therefore,	in	the	
present	experiment,	a	simple	protein	precipitation	procedure	
was	developed	to	reduce	sample	preparation	time.	No	further	
concentration	 procedure	 was	 needed	 and	 the	 sample	
preparation	 procedure	 was	 simplified.	 To	 test	 extraction	
efficiency,	 three	 different	 protein	 precipitation	 agents	
(acetonitrile,	 methanol,	 and	 acetone)	 were	 investigated.	
Acetonitrile	had	a	higher	efficiency	of	precipitation	of	protein	
with	minimal	loss	of	extracted	drug	sample.	
	
		
(a)	
		
(b)	
	
Figure	2.	Typical	chromatogram	of	metformin	hydrochloride	(Rt:	2.00	min)	
(a)	and	chlorpheniramine (Rt:	2.10	min)	(b).	
	
3.3.	Method	validation	
	
3.3.1.	Selectivity	
	
Selectivity	 is	 defined	 as	 the	 ability	 of	 a	 chromatographic	
method	 to	 measure	 a	 response	 of	 the	 analyte	 without	
interference	 from	the	biological	matrix.	This	was	assessed	by	
evaluating	 six	 individual	 lots	 of	 human	 plasma	 with	 the	
corresponding	 spiked	 plasma.	 There	 were	 no	 endogenous	
peaks	 that	 interfered	 with	 the	 quantitation	 of	 metformin	
hydrochloride	or	internal	standard.		
	
3.3.2.	Linearity	and	LLOQ	
	
The	 standard	 calibration	 curves	 for	 metformin	
hydrochloride	was	linear	over	the	concentration	range	of	5.00‐
4000.00	 ng/mL	 (r2	 >	 0.999).	 The	 typical	 equations	 for	 the	
calibration	 curves	 for	 metformin	 hydrochloride	 was	 y	 =	
0.0005‐0.0074x	&	r2	=	0.9997.	The	lower	limit	of	quantification	
for	 metformin	 hydrochloride	 was	 10.000	 ng/mL.	 A	 typical	
chromatogram	is	shown	in	Figure	2.	
	
3.3.3.	Precision,	accuracy	and	dilution	integrity	
	
Table	 1	 shows	 the	 validation	 data	 on	 accuracy	 of	 each	
standard	 concentration.	 The	 CVs	 for	 the	 back‐calculated	
calibration	standards	at	5.00	and	4000.0	ng/mL	were	1.9	and	
1.1%,	 respectively.	 The	 precision	 and	 accuracy	 data	 for	 QCs	
are	 summarized	 in	 Table	 2.	 For	 QCs	 at	 10.00,	 2000.00	 and	
4000.00	ng/mL,	inter‐assay	CV	values	were	1.5,	0.4	and	2.0%,	
respectively,	and	the	percentage	of	nominal	ranged	from	99.0	
to	101.8%.	Intra‐assay	CV	values	for	QCs	at	10,	2000	and	4000	
ng/mL	were	2.1,	0.9	and	1.3	%,	and	the	percentage	of	nominal	
ranged	 from	 98.9	 to	 105.5%.	 These	 CV	 and	 percentage	 of	
nominal	 values	 indicate	 reproducibility	 and	 reliability	 of	 the	
UPLC‐MS/MS	method.		
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Table	2.	Precision	for	the	determination	of	metformin	hydrochloride	and	in	human	plasma.	
Added	concentration	of	metformin	hydrochloride	(ng/mL)		 CV	(%)	a
Intra‐day Inter‐day	
10.00	 2.1 1.5	
2000.00	 0.9 0.4	
4000.00	 1.3 2.0	
a	CV,	coefficient	of	variation.	
	
Table	3.	Stability	of	metformin	hydrochloride	in	human	plasma,	n	=	6.	
Storage	stability	conditions	 Statistical	parameters	 Metformin,	ng/mL	
10.000 2000.00	 4000.00
Bench	top	stability	(8	h)	 Found	mean	plasma	conc.	 9.93	 2049.00	 4071.20	
SD	a	 0.35 24.79	 85.50
CV	b	 3.52	 1.21	 2.10	
Percentage	of	nominal 99.31 102.45	 101.78
Three	freeze‐thaw	cycles	 Found	mean	plasma	conc. 10.15 1989.20	 4084.80
SD	a	 0.152	 39.78	 52.00	
CV	b 1.50 2.00	 1.30	
Percentage	of	nominal	 101.52	 99.46	 102.12	
Long‐term	stability	(30	days)	 Found	mean	plasma	conc. 11.02 2110.60	 4338.80
SD	a	 0.69 45.00	 160.97
CV	b	 6.25	 2.13	 3.71	
Percentage	of	nominal 110.21 105.53	 108.47
a	SD,	standard	deviation.	
b	CV,	coefficient	of	variation.	
	
Table	4.	Pharmacokinetics	 parameters	of	metformin	hydrochloride	 after	 administration	 of	 single	 oral	 dose	of	Mepaphage	500	mg	Tablet,	 the	 test	product	
(MEPACO,	Egypt.)	and	Glucophage	500	mg	Tablet,	the	reference	product	(Merck	Sante,	S.A.S.,	France).	
Phramacokinetic	parameter	 Mepaphage	(Test	drug)	(Mean±SD)	 Glucophage	(Reference	drug)	(Mean±SD)	
AUC0‐t	(ng.h/mL)	 4595±2070 4837±2794
AUC0‐∞	(ng.h/mL)	 4808±2115 5079±2840
Cmax	(ng/mL)	 711±429 747±557
Tmax	(h)	(Median)	 2.5	 2.5	
Kel	(h‐1)	 0.115±0.045	 0.12±0.051	
T1/2	(h)	 7.12±3.3	 7.27±3.95	
	
	
3.3.4.	Recovery	
	
The	extraction	recovery	was	determined	by	comparing	the	
peak	 areas	 of	 extracted	 plasma	 QC	 samples	 at	 10,	 2000	 and	
4000	 ng/mL	 levels	 to	 the	 peak	 areas	 of	 metformin	
hydrochloride	in	solvent	at	the	corresponding	concentrations.	
The	 average	 recovery	 for	 metformin	 hydrochloride	 was	
97.0%.	
	
3.3.5.	Stability	of	the	analyte	
	
Stock	 solution	 of	 analyte	 and	 IS	 were	 stable	 at	 room	
temperature	for	22	h	and	at	2‐8	°C	for	30	days.	The	analyte	in	
control	human	plasma	at	room	temperature	was	stable	at	least	
for	 8	 h	 (bench	 top	 stability),	 stable	 for	 minimum	 of	 three	
freeze	and	 thaw	cycles.	 Spiked	plasma	samples,	 stored	at	 ‐70	
°C	for	long	term	stability	experiment,	were	stable	for	minimum	
of	 30	 days.	 Different	 stability	 experiments	 in	 plasma	 with	
values	for	precision	and	percent	change	are	shown	in	Table	3.	
	
3.4.	Bioequivalence	study	
	
The	 present	 method	 was	 successfully	 applied	 to	 a	
bioequivalence	 study	 of	 metformin	 hydrochloride	 after	 oral	
administration	 of	 two	 brands	 of	 metformin	 hydrochloride	
(Mepaphage	 500	 mg	 tablet	 MEPACO,	 Elsharkya,	 Egypt	 and	
Glucophage	 500	 mg	 film	 coated	 tablet	 MERCK	 SANTE	 S.A.S.,	
France)	in	24	healthy	volunteers.	Mean	plasma	concentration‐
time	curves	of	metformin	hydrochloride	in	a	single	dose	study	
are	 shown	 in	 Figure	 3.	 Bioequivalence	 criteria	 were	met	 for	
the	 Mepaphage	 500	 mg	 tablet	 formulation	 relative	 to	 the	
Glucophage	 500	 mg	 film	 coated	 tablet	 formulation	 as	 the	
corresponding	 94.7%.	 The	 pharmacokinetic	 parameters	 are	
shown	in	Table	4.		
	
4.	Conclusion	
	
A	 relatively	 simple,	 accurate,	 precise	 and	 rapid	 method	
suitable	 for	 the	determination	of	metformin	hydrochloride	 in	
plasma	 for	 bioequivalence	 studies	 was	 developed	 and	
validated.	 This	 method	 has	 several	 advantages	 compared	 to	
previously	 reported	methods	 such	 as	 using	 of	 UPLC	 column,	
reducing	flow	rate	and	consequently	decreased	the	volume	of	
organic	solvent	used	in	the	mobile	phase	and	time	of	analysis	
(about	 0.5	 min).	 In	 addition,	 the	 method	 was	 comparatively	
simple,	 due	 to	 the	 use	 of	 direct	 solvent	 extraction	 and	
provided	accuracy	and	precision,	which	was	better	than	most	
previously	reported	methods.	The	current	relatively	very	short	
run	 time	 of	 0.5	min.	 has	 the	 advantage	 of	 facilitating	 and	
enhancing	 the	 efficiency	 of	 processing	 large	 numbers	 of	
plasma	 samples	 obtained	 from	 bioequivalence	 studies	 in	
healthy	human	subjects.	
	
	
Figure	3.	Mean	plasma	concentration	of	metformin	after	administration	of	
single	 oral	 dose	 of	 Mepaphage	 (Metformin	 hydrochloride)	 500	 mg	 Film	
Coated	Tablet,	the	test	product	(MEPACO,	Elsharkya,	Egypt)	and	Glucophage	
(Metformin	 hydrochloride)	 500	 mg	 Film	 Coated	 Tablet,	 the	 reference	
product	(Merck	Sante,	S.A.S.,	France)	in	24	healthy	volunteers.	
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